Clinical Trial Update: S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial S1613 evaluated trastuzumab plus pertuzumab versus cetuximab plus irinotecan in locally advanced or metastatic HER2-amplified colorectal cancer th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• IRINOTECAN HYDROCHLORIDE (irinotecan hydrochloride)
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Colon Adenocarcinoma, ERBB2 Gene Amplification | Phase 2 | Status: COMPLETED | Results posted: 2024-02-07